Integra LifeSciences Holdings Corp: announces Q3 2026 financial results

What happened

• On Oct 21, 2026, Integra LifeSciences Holdings Corporation announced financial results for the quarter ended Sep 30, 2026 in a press release and included reconciliations of GAAP to various non-GAAP measures for the quarters ended Sep 30, 2026 and Sep 30, 2025.
• The press release provided forward-looking guidance regarding organic revenues and adjusted earnings per diluted share but did not provide reconciliations to the most directly comparable forward-looking GAAP financial measures because, as stated in the filing, "certain GAAP expense items and the impact of changes in foreign exchange rates are highly variable and management is unable to predict them with reasonable certainty and without unreasonable effort."

Key details

• The filing reports reconciliations for: GAAP revenues to organic revenues; GAAP net income to adjusted EBITDA; GAAP net income to adjusted net income; GAAP gross profits to adjusted gross profits; GAAP gross margin to adjusted gross margin; GAAP earnings per diluted share to adjusted earnings per diluted share for the quarters ended Sep 30, 2026 and Sep 30, 2025.
• The filing also reconciled GAAP total debt to net debt for the quarter ended Sep 30, 2026 and for the period ended Dec 31, 2025.
• The filing was made under Item 2.02, results of operations and financial condition.

Why it may matter

• Item 2.02 reports results of operations and financial condition and, in this case, covers the company’s Oct 21, 2026 press release announcing Q3 2026 results, related non-GAAP reconciliations for specified periods, and forward-looking guidance without GAAP reconciliations for the reasons stated by management.
• This filing does not show why the insider traded or why the company acted.